The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC.

Christian Rolfo,Nele Van Der Steen,Patrick Pauwels,Pablo Reclusa,Godefridus J. Peters,Elisa Giovannetti

The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC.

2017

Christian Rolfo
Nele Van Der Steen
Patrick Pauwels
Pablo Reclusa
Godefridus J. Peters
Elisa Giovannetti

e20043Background: Targeted therapies caused a revolution in treatment of non-small cell lung cancer (NSCLC). Response to Epidermal Growth Factor Receptor such as erlotinib, can be predicted by the ...

Keywords:

PI3K/AKT/mTOR pathway
Protein kinase B
Wild type
Erlotinib
Pathology
Cancer research
Crizotinib
Medicine
Epidermal growth factor receptor
non small cell
pi3k akt signaling

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations